Get the Stockscreener App
118.73
1.00%
-1.2102
Biontech Se Adr stock is traded at $118.73, with a volume of 192.32K.
It is down -1.00% in the last 24 hours and down -6.41% over the past month.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
See More
Previous Close:
$119.94
Open:
$119.47
24h Volume:
192.32K
Relative Volume:
0.25
Market Cap:
$28.75B
Revenue:
$3.30B
Net Income/Loss:
$-501.07M
P/E Ratio:
-56.15
EPS:
-2.1146
Net Cash Flow:
$1.03B
1W Performance:
-4.06%
1M Performance:
-6.41%
6M Performance:
+49.84%
1Y Performance:
+24.93%
1-Day Range:
$117.49
$120.18
1-Week Range:
$115.02
$124.37
52-Week Range:
$76.53
$131.49
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.85 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.03 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
650.78 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.88 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Nov-19-24 | Initiated | Berenberg | Buy |
| Nov-19-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-08-24 | Upgrade | Goldman | Neutral → Buy |
| Sep-24-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-16-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-07-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-02-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-14-24 | Initiated | Evercore ISI | In-line |
| Feb-23-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-24 | Initiated | Oppenheimer | Perform |
| Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-17-23 | Upgrade | Redburn | Neutral → Buy |
| Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-17-22 | Initiated | Cowen | Market Perform |
| Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
| May-18-21 | Initiated | Goldman | Neutral |
| May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-03-20 | Resumed | Berenberg | Buy |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
| Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-22-20 | Downgrade | UBS | Buy → Neutral |
| Nov-05-19 | Initiated | Wolfe Research | Outperform |
| Nov-04-19 | Initiated | Berenberg | Buy |
| Nov-04-19 | Initiated | BofA/Merrill | Buy |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Nov-04-19 | Initiated | JP Morgan | Overweight |
| Nov-04-19 | Initiated | SVB Leerink | Outperform |
| Nov-04-19 | Initiated | UBS | Buy |
View All
Biontech Se Adr Stock (BNTX) Latest News
North Texas Took Center Stage at Advanced Therapies Week 2025, Highlighting Innovation and Collaboration in Life Sciences - GlobeNewswire Inc.
BioNTech SE ADR (BNTX) did well last session? - US Post News
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales - Yahoo Finance
Moderna and BioNTech shares fall after Senate committee vote on RFK Jr. - Investing.com
Hesai Group ADR (HSAI) shows promising results - US Post News
Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings? - Yahoo Finance
Validea Benjamin Graham Strategy Daily Upgrade Report1/31/2025 - Nasdaq
BioNTech's SWOT analysis: oncology pipeline, cash boost stock outlook - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Stocks To Watch: BioNTech ADR Sees Relative Strength Rating Rise To 84 - Inkl
Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know - MSN
Years-Old List of Alleged Pfizer COVID-19 Vaccine 'Side Effects' Is Misleading - Snopes.com
BioNTech Expands Cancer Drug Pipeline: Launches Key Lung Cancer Trials, Advances Immunotherapy Programs - StockTitan
Why BioNTech (BNTX) Shares Are Volatile TodayBioNTech (NASDAQ:BNTX) - Benzinga
BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch
What’s Behind The Recent Rise In MRNA Stock? - Forbes
BioNTech SE ADR rises Tuesday, outperforms market - MarketWatch
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike - Investor's Business Daily
BioNTech SE ADR rises Monday, outperforms market - MarketWatch
BNTX: 3 Genomic Stocks Unlocking the Secrets of DNA - StockNews.com
BioNTech SE ADR rises Friday, still underperforms market - MarketWatch
BioNTech SE ADR rises Thursday, outperforms market - MarketWatch
Russia develops mRNA cancer vaccine for citizens, skepticism lingers - Mugglehead
BioNTech SE ADR falls Monday, underperforms market - MarketWatch
BioNTech SE ADR rises Friday, outperforms market - MarketWatch
BioNTech SE ADR falls Thursday, underperforms market - MarketWatch
BioNTech SE ADR rises Tuesday, still underperforms market - MarketWatch
BioNTech SE ADR rises Monday, still underperforms market - MarketWatch
Stocks Generating Improved Relative Strength: BioNTech ADR - Investor's Business Daily
BioNTech's SWOT analysis: mRNA pioneer's stock faces oncology pipeline test - Investing.com
BioNTech SE ADR falls Friday, underperforms market - MarketWatch
BioNTech SE ADR rises Wednesday, outperforms market - MarketWatch
BioNTech SE ADR falls Tuesday, underperforms market - MarketWatch
BioNTech's SWOT analysis: mRNA pioneer's stock balances COVID legacy, oncology future - Investing.com
Stocks Showing Improving Market Leadership: BioNTech ADR Earns 81 RS Rating - Investor's Business Daily
BioNTech ADR Earns Relative Strength Rating Upgrade - Investor's Business Daily
BioNTech's SWOT analysis: oncology pipeline fuels stock's potential amid market volatility - Investing.com
Biontech Se Adr Stock (BNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):